Nodular lymphocyte predominant B-cell lymphoma

Clinical trials for Nodular lymphocyte predominant B-cell lymphoma explained in plain language.

Never miss a new study

Get alerted when new Nodular lymphocyte predominant B-cell lymphoma trials appear

Sign up with your email to follow new studies for Nodular lymphocyte predominant B-cell lymphoma, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Trials to join now! 1 Not yet finished but already full! 1

New drug mosunetuzumab takes on rituximab in rare lymphoma trial

Disease control Recruiting now

This phase 2 trial tests whether mosunetuzumab, a newer antibody, works better than the standard rituximab for nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL). About 70 patients with untreated or previously treated NLPHL will receive one of the two drugs. The main goal is…

Matched conditions: NODULAR LYMPHOCYTE PREDOMINANT B-CELL LYMPHOMA

Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control

Last updated Sep 02, 2026 00:00 UTC

Nodular lymphocyte predominant B-cell lymphoma

Get alerted when new Nodular lymphocyte predominant B-cell lymphoma trials appear

New drug mosunetuzumab takes on rituximab in rare lymphoma trial